ImClone Systems and partner Bristol-Myers Squibb expect results in the next few weeks on whether their cancer drug shows positive Phase III trial results for treating pancreatic cancer. One analyst said the drug could have an upside in peak sales of $100 million to $250 million if the results are positive.

Full Story:

Related Summaries